|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum complexes between C1INH and C1INH autoantibodies for the diagnosis of acquired angioedema.
|
31397881 |
2019 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angioedema due to acquired deficiency of the inhibitor of the first component of complement (C1-INH) is a rare disease known as acquired angioedema (AAE).
|
30073422 |
2018 |
|
Acquired angioedema
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Xanthoderma related to antiflavin activity of the monoclonal component or acquired angioedema related to anti-C1INH activity is other example.
|
27501129 |
2017 |
|
Acquired angioedema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
According to this classification, three types of hereditary angioedema (genetic C1-INH deficiency, normal C1-INH with factor XII mutations, and unknown origin) and four types of acquired angioedema (C1-INH deficiency, related to ACE inhibitors intake, idiopathic histaminergic, and idiopathic non-histaminergic) are presented.
|
27113957 |
2016 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
CTD_human |
Acquired C1 inhibitor (C1-INH) deficiency exposes patients to angioedema recurrences (acquired angioedema [AAE]) mediated by bradykinin pathway activation.
|
23406939 |
2013 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Advances in our understanding of the complex effects of C1-INH deficiency at molecular level have led to new targeted approaches to the treatment of HAE and AAE.
|
23137231 |
2013 |
|
Acquired angioedema
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Acquired C1 inhibitor (C1-INH) deficiency exposes patients to angioedema recurrences (acquired angioedema [AAE]) mediated by bradykinin pathway activation.
|
23406939 |
2013 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acquired C1 inhibitor (C1-INH) deficiency exposes patients to angioedema recurrences (acquired angioedema [AAE]) mediated by bradykinin pathway activation.
|
23406939 |
2013 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hereditary and acquired angioedema are known to be a result of abnormalities in C1 inhibitor protein while the mechanism of drug-induced and idiopathic angioedema is less clear.
|
19331715 |
2009 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although anti-C1-INH titers (type I AAE) were normal initially, we observed a sharp increase in anti-C1-INH titers (suggestive of type II AAE) during follow-up.
|
18204284 |
2008 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
New treatments (recombinant C1 inhibitor, icatibant, DX-88, and for acquired angioedema, rituximab) so far show good safety profiles.
|
17547847 |
2007 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of C1q can help differentiate between HAE and AAE caused by C1-INH deficiency.
|
16835976 |
2006 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency.
|
16630950 |
2006 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Causes and management of acquired angioedema and a new type of angioedema with normal C1-INH are also discussed.
|
15356535 |
2004 |
|
Acquired angioedema
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Plasma bradykinin in angio-oedema.
|
9734886 |
1998 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
CTD_human |
Plasma bradykinin in angio-oedema.
|
9734886 |
1998 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
In our experience the majority of patients with acquired angioedema (16 of 18) have autoantibodies to C1-INH in their serum.
|
9777420 |
1998 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hereditary and acquired C1-inhibitor (C1-INH) deficiencies (hereditary angioedema, HAE and acquired angioedema, AAE) are characterized by episodic increases in vasopermeability due to kinin release.
|
8856187 |
1996 |
|
Acquired angioedema
|
0.400 |
Biomarker
|
disease |
BEFREE |
The patient with HAE was administered 500 units of C1 INH intravenously every 4 or 5 days, whereas the patient with acquired angioedema required 1000 units of C1 INH every 5 days.
|
2926086 |
1989 |